Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Vivus grants Menarini marketing rights to Spedra in Europe, Australia, and New Zealand

Executive Summary

Menarini Group has received rights to market Vivus Inc.’s (focused on sexual health and metabolic and respiratory conditions) Spedra (avanafil) in over 40 European countries, Australia, and New Zealand. Spedra is a phosphodiesterase-5 inhibitor that was approved in the US in early 2012 (as Stendra) and in Europe last month for erectile dysfunction.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Manufacturing or Supply
    • Marketing (Licensing)

Related Companies